TILT-123 (igrelimogene litadenorepvec) is an engineered OVs that selectively replicates in cancer cells and expresses dual transgenes IL-2 and TNF-α, designed to enhance tumor immune infiltration and cytotoxic T-cell responses [187]. This evidence concerns the gene IL2 and neoplasm.